[go: up one dir, main page]

DK3209319T3 - En fremgangsmåde til behandling af svampeinfektioner - Google Patents

En fremgangsmåde til behandling af svampeinfektioner Download PDF

Info

Publication number
DK3209319T3
DK3209319T3 DK15852021.3T DK15852021T DK3209319T3 DK 3209319 T3 DK3209319 T3 DK 3209319T3 DK 15852021 T DK15852021 T DK 15852021T DK 3209319 T3 DK3209319 T3 DK 3209319T3
Authority
DK
Denmark
Prior art keywords
procedure
treating fungi
fungi infections
infections
treating
Prior art date
Application number
DK15852021.3T
Other languages
English (en)
Inventor
Der Weerden Nicole Louise Van
Marilyn Anne Anderson
Original Assignee
Hexima Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55748162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3209319(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexima Ltd filed Critical Hexima Ltd
Application granted granted Critical
Publication of DK3209319T3 publication Critical patent/DK3209319T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DK15852021.3T 2014-10-21 2015-05-29 En fremgangsmåde til behandling af svampeinfektioner DK3209319T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066808P 2014-10-21 2014-10-21
PCT/AU2015/050293 WO2016061619A1 (en) 2014-10-21 2015-05-29 A method of treatment

Publications (1)

Publication Number Publication Date
DK3209319T3 true DK3209319T3 (da) 2021-10-04

Family

ID=55748162

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15852021.3T DK3209319T3 (da) 2014-10-21 2015-05-29 En fremgangsmåde til behandling af svampeinfektioner

Country Status (24)

Country Link
US (4) US9713632B2 (da)
EP (2) EP3949977A1 (da)
JP (3) JP6646662B2 (da)
KR (1) KR102472312B1 (da)
CN (3) CN107106647B (da)
AU (2) AU2015336933B2 (da)
BR (1) BR112017008211A2 (da)
CA (1) CA2965187A1 (da)
CY (1) CY1124640T1 (da)
DK (1) DK3209319T3 (da)
ES (1) ES2890461T3 (da)
HR (1) HRP20211477T8 (da)
HU (1) HUE056178T2 (da)
LT (1) LT3209319T (da)
MX (2) MX382906B (da)
MY (1) MY186552A (da)
NZ (1) NZ731143A (da)
PL (1) PL3209319T3 (da)
PT (1) PT3209319T (da)
RS (1) RS62386B1 (da)
SG (2) SG11201703184SA (da)
SI (1) SI3209319T1 (da)
SM (1) SMT202100558T1 (da)
WO (1) WO2016061619A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573980B2 (en) 2013-03-15 2017-02-21 Spogen Biotech Inc. Fusion proteins and methods for stimulating plant growth, protecting plants from pathogens, and immobilizing Bacillus spores on plant roots
WO2015161348A1 (en) * 2014-04-24 2015-10-29 Hexima Limited Agents and methods of treatment
IL315468A (en) 2014-09-17 2024-11-01 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
EP3949977A1 (en) 2014-10-21 2022-02-09 Hexima Limited A method of treatment
AU2015396744B2 (en) * 2015-05-29 2020-04-16 Hexima Limited A method of in vivo treatment
WO2019060574A1 (en) 2017-09-20 2019-03-28 Spogen Biotech Inc. FUSION PROTEINS, RECOMBINANT BACTERIA AND EXIN FRAGMENTS FOR PLANT HEALTH
US12053486B2 (en) 2018-03-09 2024-08-06 Therazure LLC Compositions for the treatment of infections in feet

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3298368A (en) 1964-04-24 1967-01-17 Charos Peter Heated cream applicator gloves
US4087675A (en) 1977-02-07 1978-05-02 Coretta Sansonetti Heated mitten
US4241080A (en) * 1979-05-29 1980-12-23 The Dow Chemical Company Stabilized aqueous antimicrobial composition
US4267852A (en) 1979-09-17 1981-05-19 Hullinger Judith E Process for enhancing and strengthening the growth of nails
JPS5775663A (en) 1980-07-22 1982-05-12 Kiichirou Sarui Apparatus for treating dermatophytosis
US5181914A (en) 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5098415A (en) 1990-10-09 1992-03-24 Jack Levin Device and method for using an aqueous solution containing ozone to treat foot diseases
US5156591A (en) 1990-12-13 1992-10-20 S. I. Scientific Innovations Ltd. Skin electrode construction and transdermal drug delivery device utilizing same
JPH0657323A (ja) 1992-08-06 1994-03-01 Sumitomo Metal Ind Ltd 加熱炉におけるバーナー制御方法
JPH0728521A (ja) 1993-07-09 1995-01-31 Yaskawa Electric Corp シミュレーションプログラム自動作成方法
US5449658A (en) 1993-12-07 1995-09-12 Zeneca, Inc. Biocidal compositions comprising polyhexamethylene biguanide and EDTA, and methods for treating commercial and recreational water
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5668084A (en) 1995-08-01 1997-09-16 Zeneca Inc. Polyhexamethylene biguanide and surfactant composition and method for preventing waterline residue
US5795314A (en) 1996-06-19 1998-08-18 Berenstein; Moshe Therapeutic fingernail treatment device
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US5981698A (en) * 1997-06-03 1999-11-09 Cyberchemics, Inc. Antimicrobial polypeptides
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US6727401B1 (en) 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6235047B1 (en) 1998-04-06 2001-05-22 Augustine Medical, Inc. Wound treatment apparatus with a heater, a heat conductive bandage, and heat-spreading means acting between the heater and bandage
US6572580B2 (en) 1998-08-06 2003-06-03 Profoot, Inc. Set depth nail notcher with patch system and method for treating nail fungus
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US6477410B1 (en) 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
US6528697B1 (en) 2000-01-03 2003-03-04 Augustine Medical, Inc. Modular bandage
US6281239B1 (en) 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
CN101029308B (zh) * 2001-02-08 2012-07-25 赫希玛有限公司 植物来源分子、其编码遗传序列及其用途
US6585963B1 (en) 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
WO2002100174A1 (fr) 2001-06-08 2002-12-19 K.I Chemical Industry Co., Ltd. Deodorant liquide tuant les micro-organismes et procede de desodorisation tuant les micro-organismes
EP2270188A3 (en) 2001-06-22 2011-09-07 Pioneer Hi-Bred International, Inc. Defensin polynucleotides and methods of use
US6821508B2 (en) 2001-06-27 2004-11-23 Rutgers, The State University Composition and method for topical nail treatment
JP2003123136A (ja) 2001-10-17 2003-04-25 Toshiba Electric Appliance Co Ltd 飲料提供装置
US20030144625A1 (en) 2002-01-28 2003-07-31 Garry Sherman Method and apparatus for the treatment of infections of the nail matrix and nail plate
US6634367B2 (en) 2002-03-25 2003-10-21 Kathleen Hunter Abraham Sealing enclosure for finger tips
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US6921529B2 (en) 2002-07-29 2005-07-26 Joseph C. Maley Treatment modality and method for fungal nail infection
CN1678277B (zh) 2002-07-29 2010-05-05 艾克里麦德公司 治疗皮肤病的方法和组合物
US20070292355A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US20040161452A1 (en) 2003-02-18 2004-08-19 Petit Michael G. Drug-dispensing dressing and composition for treating onychomycosis
US7647100B2 (en) 2003-07-14 2010-01-12 Power Paper Ltd. Method, apparatus, and kit for onychomycosis treatment
US20050261755A1 (en) 2004-05-24 2005-11-24 Bacino John E Conformable heat transfer pack
US20060013862A1 (en) 2004-07-19 2006-01-19 Held Jerry M Onychomycosis: a new process for cure
JP2006075357A (ja) 2004-09-09 2006-03-23 Institute Of Physical & Chemical Research 水虫の治療装置
ZA200707408B (en) 2005-02-16 2009-11-25 Anacor Pharmaceuticals Inc Boron-containing small molecules
JP2008540050A (ja) 2005-05-18 2008-11-20 タイレル、インク 熱を印加して皮膚病変を治療するための治療装置および方法
US7793666B2 (en) 2005-07-28 2010-09-14 Innovation Biomedical Devices, Inc. Apparatus and method for treatment of infected nail
US20070104664A1 (en) 2005-10-26 2007-05-10 California Institute Of Technology Treatment of toenail fungus
JP2009526751A (ja) 2005-12-30 2009-07-23 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
US8106031B2 (en) 2006-05-02 2012-01-31 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
JP2010529897A (ja) 2007-06-15 2010-09-02 ニトリツク・バイオ・セラピユーテイクス・インコーポレーテツド 動電学的薬剤配送の電流集中緩和方法とシステム
US20090048590A1 (en) 2007-08-15 2009-02-19 Tyrell, Inc. Systems and methods for treating nail-bed fungus through application of heat
ES2324192B1 (es) * 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.
FR2942716B1 (fr) * 2009-03-06 2011-04-15 Galderma Res & Dev Methode de solubilisation d'agent antifongique et compositions a haute concentration en agent antifongique applicables sur l'ongle
IT1395241B1 (it) 2009-08-07 2012-09-05 Iarrera Apparato per la germinazione controllata di semi e relativo metodo.
EP2544659A2 (en) 2009-12-23 2013-01-16 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
CN103154252B (zh) * 2010-08-23 2017-05-24 先锋国际良种公司 防御素变体及其使用方法
KR101311196B1 (ko) * 2010-12-23 2013-09-27 중앙대학교 산학협력단 진균 감염 또는 뇌수막염 치료를 위한 ｕｐｒ 신호전달 유전자 ｉｒｅ1 및 ｈｘｌ1의 용도
CN103533947A (zh) * 2010-12-28 2014-01-22 卡梅迪斯有限公司 用于治疗和预防感染的植物提取物
EP2664327A1 (en) 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN104902748A (zh) 2012-11-23 2015-09-09 河西马有限公司 抗病原体方法
AU2013260696A1 (en) * 2012-11-23 2014-06-12 Hexima Limited Use of anti-fungal defensins
CA2905588C (en) 2013-03-12 2018-11-06 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
US10231450B2 (en) 2014-04-23 2019-03-19 Hexima Limited Agents and methods for treatment of pathogens
WO2015161348A1 (en) 2014-04-24 2015-10-29 Hexima Limited Agents and methods of treatment
EP3949977A1 (en) * 2014-10-21 2022-02-09 Hexima Limited A method of treatment

Also Published As

Publication number Publication date
JP7207780B2 (ja) 2023-01-18
WO2016061619A1 (en) 2016-04-28
EP3209319B1 (en) 2021-07-14
AU2015336933B2 (en) 2021-01-14
CN107106647B (zh) 2021-08-10
US20170296622A1 (en) 2017-10-19
MX2017005305A (es) 2017-08-02
US20170239328A1 (en) 2017-08-24
HRP20211477T8 (hr) 2022-03-04
HRP20211477T1 (hr) 2022-01-07
JP2020097573A (ja) 2020-06-25
RS62386B1 (sr) 2021-10-29
PT3209319T (pt) 2021-09-24
JP2022022316A (ja) 2022-02-03
LT3209319T (lt) 2021-10-25
MX2021006057A (es) 2021-07-06
SMT202100558T1 (it) 2021-11-12
KR20170072291A (ko) 2017-06-26
BR112017008211A2 (pt) 2017-12-26
US9713632B2 (en) 2017-07-25
JP6646662B2 (ja) 2020-02-14
EP3949977A1 (en) 2022-02-09
US20160106807A1 (en) 2016-04-21
AU2021201810A1 (en) 2021-04-22
CN107106647A (zh) 2017-08-29
EP3209319A1 (en) 2017-08-30
KR102472312B1 (ko) 2022-11-29
JP2017533210A (ja) 2017-11-09
US10010576B2 (en) 2018-07-03
NZ731143A (en) 2021-07-30
SG11201703184SA (en) 2017-05-30
AU2021201810B2 (en) 2024-08-22
MX382906B (es) 2025-03-13
HUE056178T2 (hu) 2022-01-28
JP6990224B2 (ja) 2022-02-03
PL3209319T3 (pl) 2021-12-20
CN118453831A (zh) 2024-08-09
EP3209319A4 (en) 2018-05-16
SG10201912688YA (en) 2020-02-27
US11446354B2 (en) 2022-09-20
CN113368215A (zh) 2021-09-10
SI3209319T1 (sl) 2022-01-31
MY186552A (en) 2021-07-26
CA2965187A1 (en) 2016-04-28
CY1124640T1 (el) 2022-07-22
AU2015336933A1 (en) 2017-05-11
US20210228678A1 (en) 2021-07-29
ES2890461T3 (es) 2022-01-19
US10973874B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
IL249981A0 (en) Method
DK3110988T3 (da) Metoder til behandling af lithiumholdige materialer
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3359095T3 (da) Automatiseret hånd
PT3298027T (pt) Compostos depsipéptidos antelmínticos
DK3125898T3 (da) Farmakofor til trail-induktion
DK3341479T3 (da) LNA-G-Proces
HUE057118T2 (hu) Folyamat
DK3393468T3 (da) Fremgangsmåder til behandling af en immundefektsygdom
HUE048685T2 (hu) Antimikotikus vegyület
EP3559207A4 (en) XYLITOL-PRODUCING METSCHNIKOWIA SPECIES
DK3209319T3 (da) En fremgangsmåde til behandling af svampeinfektioner
HUE054351T2 (hu) Vegyületek
DK3597189T3 (da) Krystallinske forbindelser
EP3498837A4 (en) Genome editing method
DE112015002984A5 (de) Positioniereinheit
UY4467S (es) Frasco
DK3855181T3 (da) Forbindelser til behandling af lipofuscinrelaterede sygdomme
EP3523659C0 (en) MULTI-PROTEASE PROCESS
IL251479B (en) Compositions
LT3331885T (lt) Junginiai
DK2942098T3 (da) Forbedret fremgangsmåde til fjernelse af nitrit
IL254336A0 (en) Novel treatment method
DK3194652T3 (da) Kontinuerlig fremgangsmåde til at behandle en lignocellulosisk biomasse